Emerging Therapies

Novel Drug “Home Run” for TRK Mutation–Positive Tumors
Phoebe Starr
TOP - November 2017, Vol 10, No 4 - Emerging Therapies
Chicago, IL—Larotrectinib (LOXO-101), an investigational agent that targets tropomyosin receptor kinase (TRK) fusions, has demonstrated excellent, consistent, and durable antitumor activity in a range of tumor types in adults and children, reported lead investigator David M. Hyman, MD, Chief, Early Drug Development Service, Memorial Sloan Kettering Cancer Center, New York City, at the 2017 ASCO annual meeting.
Read More
Mogamulizumab, Anti-CCR4 Antibody, Improves Survival in Patients with Advanced Cutaneous T-Cell Lymphoma
Charles Bankhead
Web Exclusives - Emerging Therapies

“Mogamulizumab demonstrated convincing clinical activity, not just in skin but also in clearing malignant T-cells in the blood and lymph nodes. PFS and overall global response outcomes are clearly superior,” said Dr Kim.

Read More
First-in-Class Sotatercept Improves Hemoglobin Levels in Anemic Patients with Myelofibrosis
Wayne Kuznar
Web Exclusives - Emerging Therapies

Of the 24 patients receiving sotatercept monotherapy, 20 had primary myelofibrosis. Their median baseline hemoglobin level was 7.5 g/dL.

Read More
LOXO-292 Highly Effective in RET-Positive Cancers
Web Exclusives - Emerging Therapies
The investigational LOXO-292, a potent and highly selective RET kinase inhibitor, has demonstrated robust and durable antitumor activity against RET-activating fusions and mutations, and has shown promising efficacy in patients with solid tumors and RET mutations.
Read More
Selective RET Inhibitor, BLU-667, Hits the Target in Patients with Lung or Thyroid Cancers
Phoebe Starr
TOP - November 2018, Vol 11, No 3 - Emerging Therapies
“Tumor reductions and durable responses were observed in most patients, especially those whose cancers progressed with chemotherapy and multikinase inhibitors,” said Vivek Subbiah, MD, at the 2018 AACR meeting.
Read More
TLR9 Agonist plus Immunotherapy May Overcome Resistance to PD-1 Inhibition
Phoebe Starr
TOP - November 2018, Vol 11, No 3 - Emerging Therapies
A novel approach using the investigational toll-like receptor 9 (TLR9) agonist CMP-001 in combination with pembrolizumab (Keytruda) may have the potential to reverse resistance to anti–PD-1 therapy, according to data from a preliminary phase 1b clinical trial.
Read More
Targeted Therapy Has Significant Activity as Second-Line Treatment of Cholangiocarcinoma with FGFR Mutations
TOP - February 2019, Vol 12, No 1 - Emerging Therapies
Treatment options are few for patients with cholangiocarcinoma whose disease progresses while receiving first-line treatment with gemci­tabine (Gemzar) and cisplatin (Platinol), with no established second-line regimen.
Read More
Single-Agent ONC201 Induces Responses in Patients with Hard-to-Treat Recurrent High-Grade Glioma
Wayne Kuznar
TOP - August 2019, Vol 12, No 3 - Emerging Therapies
High-grade gliomas harboring the histone 3 (H3) K27M mutation are lethal brain tumors associated with a poor prognosis.
Read More
Neoantigens Are Effective Targets for Developing Cancer Vaccines
Wayne Kuznar
TOP - November 2019, Vol 12, No 4 - Emerging Therapies

Chicago, IL—Tumor-specific antigens provide personalized targets for immunotherapy. Neoantigen vaccines are a new type of immunotherapy that can elicit immune response and achieve remission. Evidence is compelling to support neoantigens as the target of effective immune responses against cancer and to support an association between neoantigen load with improved clinical outcome, said Patrick Alexander Ott, MD, PhD, Clinical Director, Center for Immuno-Oncology, Dana-Farber Cancer Institute, Boston, MA, at ASCO 2019.

Read More
Sitravatinib, Novel TKI, plus Nivolumab Elicits Good Responses in Renal-Cell Carcinoma
Phoebe Starr
TOP - May 2020, Vol 13, No 3 - Emerging Therapies
San Francisco, CA—The combination of nivolumab (Opdivo) plus the investigational drug sitravatinib improved progression-free survival (PFS) in patients with pretreated metastatic clear-cell renal-cell carcinoma (RCC) and the historical disease control rates compared with nivolumab alone, according to the results of a phase 1/2 clinical trial reported at the 2020 Genitourinary Cancers Symposium.
Read More
  • 1
  • 2
Page 1 of 2
Results 1 - 10 of 19